Pfizer

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Trade Pfizer 24 hours a day, five days a week on Robinhood.

Robinhood gives you the tools to revolutionize your trading experience. Use the streamlined mobile app, or access advanced charts and execute precise trades on our browser-based platform, Robinhood Legend. Risks and limitations apply.

About PFE

Pfizer Inc. is a research-based global biopharmaceutical company, which engages in the discovery, development, manufacture, marketing, sales and distribution of biopharmaceutical products worldwide. The firm works across developed and emerging markets to advance wellness, prevention, treatments and cures that challenge the most feared diseases. 

CEO
Albert Bourla
CEOAlbert Bourla
Employees
75,000
Employees75,000
Headquarters
New York, New York
HeadquartersNew York, New York
Founded
1849
Founded1849
Employees
75,000
Employees75,000

PFE Key Statistics

Market cap
139.92B
Market cap139.92B
Price-Earnings ratio
19.27
Price-Earnings ratio19.27
Dividend yield
6.84%
Dividend yield6.84%
Average volume
38.10M
Average volume38.10M
High today
$24.75
High today$24.75
Low today
$24.51
Low today$24.51
Open price
$24.64
Open price$24.64
Volume
28.89M
Volume28.89M
52 Week high
$28.75
52 Week high$28.75
52 Week low
$23.11
52 Week low$23.11

Stock Snapshot

With a market cap of 139.92B, Pfizer(PFE) trades at $24.54. The stock has a price-to-earnings ratio of 19.27 and currently yields dividends of 6.84%.

During the trading session on 2026-07-24, Pfizer(PFE) shares reached a daily high of $24.75 and a low of $24.51. At a current price of $24.54, the stock is +0.1% higher than the low and still -0.9% under the high.

Trading volume for Pfizer(PFE) stock has reached 28.89M, versus its average volume of 38.1M.

The stock's 52-week range extends from a low of $23.11 to a high of $28.75.

The stock's 52-week range extends from a low of $23.11 to a high of $28.75.

PFE News

TipRanks 6h
Pfizer Advances New Obesity Shot With Early Stage Trial of PF-08653945

Pfizer Inc (PFE) announced an update on their ongoing clinical study. Unlock powerful investing tools with TipRanks Premium to make smarter, more confident inv...

TipRanks 6h
Pfizer’s PF-08057418 Clears Phase 1 Safety Milestone, Offering a Quiet Boost to Pipeline Confidence

Pfizer Inc (PFE) announced an update on their ongoing clinical study. Unlock powerful investing tools with TipRanks Premium to make smarter, more confident inv...

TipRanks 6h
Pfizer’s VICTORIE Study Shines Light on Cancer Clot Care and Real World Costs

Pfizer Inc (PFE) announced an update on their ongoing clinical study. Unlock powerful investing tools with TipRanks Premium to make smarter, more confident inv...

Analyst ratings

62%

of 29 ratings
Buy
31%
Hold
62.1%
Sell
6.9%

More PFE News

Simply Wall St 24h
How Investors May Respond To Pfizer Prostate Cancer Combo Drug Label Expansion Push

Earlier this week, Pfizer announced that the FDA accepted for Priority Review a supplemental application for TALZENNA plus XTANDI in men with HRR gene‑altered m...

How Investors May Respond To Pfizer Prostate Cancer Combo Drug Label Expansion Push
The Motley Fool 1d
Is Pfizer's 7% Dividend Yield Too Good to Be True? Here's the Straight Answer

We can separate high-yield dividend stocks into two broad categories. The first group consists of companies with stable businesses that generate consistent cash...

Is Pfizer's 7% Dividend Yield Too Good to Be True? Here's the Straight Answer
Nasdaq 1d
Cash Dividend On The Way From Pfizer

Looking at the universe of stocks we cover at Dividend Channel , on 7/24/26, Pfizer Inc (Symbol: PFE) will trade ex-dividend, for its quarterly dividend of $0.4...

Cash Dividend On The Way From Pfizer
TipRanks 2d
FDA grants priority review for Pfizer’s Talzena plus Xtandi

Pfizer (PFE) announced that the U.S. Food and Drug Administration accepted for Priority Review a supplemental New Drug Application for TALZENNA, an oral poly AD...

Simply Wall St 2d
Pfizer Faces New Patent Lawsuits Over Covid 19 Vaccine Technology

Arbutus Biopharma and Genevant Sciences have launched new international patent litigation against Pfizer/BioNTech over mRNA lipid nanoparticle COVID-19 vaccine...

Pfizer Faces New Patent Lawsuits Over Covid 19 Vaccine Technology
Nasdaq 2d
Want Income for Life? Here Are 3 Stocks to Buy Now and Never Sell.

Key Points Struggling drugmaker Pfizer just needs a little more time for its regrouping effort to begin bearing fruit. Beverage icon Coca-Cola is not only bui...

Want Income for Life? Here Are 3 Stocks to Buy Now and Never Sell.
Simply Wall St 3d
Pfizer Stock Seems Fairly Priced As Oncology Approvals Build

Pfizer stock has clawed back some ground over the past year but is still down sharply over five years, and the current valuation checks point to something close...

Pfizer Stock Seems Fairly Priced As Oncology Approvals Build

People also own

Based on the portfolios of people who own PFE. This list is generated using Robinhood data, and it’s not a recommendation.

Similar Marketcap

This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.

Popular Stocks

This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset

Newly Listed

This list is generated by showing companies that recently went public.

All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer. Options are risky and aren’t suitable for all investors. To learn more about risks, read the Options Disclosure Document.